News

Affymax has announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase-III program for Hematid, has completed another review. DMC has informed the company

Advaxis has received the FDA letter denying the company’s request for Orphan Drug Designation (ODD) for the use of Adxs11-001 in invasive cervix cancer. FDA stated that their

CombinatoRx has declared positive results from a Phase-I clinical study, evaluating the relative bioavailability of an oral once-daily aligned-release (AR) formulation of Synavive. The pharmacokinetic profiles observed in

Opportunities abound for overseas players like major US teaching institutions. Meanwhile, the Gulf states are also struggling with a system of health care reform. According to FT, the

Dr. John Padfield, Optos’ chairman said: On behalf of the Board I would like to thank Allan for the excellent contribution he has made to the business. Since

NPS Pharmaceuticals has presented new data from three sub-studies in patients with short bowel syndrome (SBS) who received Gattex (teduglutide) during a 24-week, placebo-controlled Phase 3 clinical trial.

EyeGate has announced that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, has improved signs and symptoms in patients with dry eye syndrome (DES).

Nabi has received scientific advice from the European Medicines Agency (EMEA) on Nicvax, regarding the requirements for marketing authorization submission, as it relates to the appropriate design of

Dave has continually proven his leadership ability by developing and implementing initiatives that increase our operational efficiencies, allowing us during this recessionary period to control costs and conserve